

Office for Research The Royal Melbourne Hospital Facsimile: +61 3 9342 8548 Level 2 South West 300 Grattan Street Parkville VIC 3050 Australia

Telephone: +61 3 9342 8530 Email: research@mh.org.au

thermh.org.au ABN 73 802 706 972

Ethical Approval

Royal Melbourne Hospital Human Research Ethics Committee

Prof Alistair G Royse The Royal Melbourne Hospital PARKVILLE 3050 VIC

11 May 2023

Dear Prof Alistair G Royse,

HREC Reference Number: HREC/92839/MH-2023 Royal Melbourne Hospital Site Reference Number: 2023.028 Project Title: Impact of Total Arterial Revascularisation in Coronary Artery Surgery on Patency, Cardiovascular, Cerebrovascular and Multiorgan Outcomes- a RCT (TA Trial)

I am pleased to advise that the above project has received ethical approval from the Royal Melbourne Hospital Human Research Ethics Committee (HREC). The HREC confirms that your proposal meets the requirements of the National Statement on Ethical Conduct in Human Research (2007). This HREC is organised and operates in accordance with the National Health and Medical Research Council's (NHRMC) National Statement on Ethical Conduct in Human Research (2007), and all subsequent updates, and in accordance with the Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95), the Health Privacy Principles described in the Health Records Act 2001 (Vic) and Section 95A of the Privacy Act 1988 (and subsequent Guidelines).

HREC Approval Date: 11 May 2023

Ethical approval for this project applies at the following sites:

| Site |
|------|
| • |

Royal Melbourne Hospital

Approved Documents:

The following documents have been reviewed and approved:

| Document | Version | Date |
|---|---------|-----------------|
| Protocol | 2.0 | 09 March 2023 |
| Master Main Participant Information Sheet/Consent Form | - | 09 March 2023 |
| CRF | 1.0 | 16 January 2023 |
| Clinical Frailty Scale | 1.2 | 2007-2009 |

PO BOX 2155 Parkville VIC 3050 Australia thermh.org.au

| EQ-5D-5L (Sample) | 1.2 | 2009 |
|---|-----|------------------|
| Lawton–Brody Instrumental Activities of Daily | - | - |
| Living Scale (IADL) | | |
| Day 1 Postop - T0+1d (Sample) | - | - |
| RMH Diagnostic Medical Physics Assessment | - | 15 February 2023 |
| (Category IIb) | | |

| Noted Document | Version | Date |
|---|---------|------|
| IT Risk and Cybersecurity Review Form – | - | - |
| Research | | |

Governance Authorisation:

Governance Authorisation is required at each site participating in the study before the research project can commence at that site.

You are required to provide a copy of this HREC approval letter to the principal investigator for each site covered by this ethics approval for inclusion in the site specific assessment application.

Conditions of Ethics Approval:

- You are required to submit to the HREC:
 - An Annual Progress Report (that covers all sites listed on approval) for the duration of the project. This report is due by 31 March each year. Continuation of ethics approval is contingent on submission of an annual report being submitted by 31 March each year. Failure to comply with this requirement may result in suspension/withdrawal of the project by the HREC.
 - A comprehensive Final Report upon completion of the project.
- Submit to the reviewing HREC for approval any proposed amendments to the project including any proposed changes to the Protocol, Participant Information and Consent Form/s and the Investigator Brochure.
- Notify the reviewing HREC of any adverse events that have a material impact on the conduct of the research in accordance with the NHMRC's Safety Monitoring and Reporting in Clinical Trials Involving Therapeutic Goods (2016) guideline.
- Notify the reviewing HREC of your inability to continue as Coordinating Principal Investigator.
- Notify the reviewing HREC of the failure to commence the study within 12 months of the HREC approval date or if a decision is taken to end the study at any of the sites prior to the expected date of completion.
- Notify the reviewing HREC of any matters which may impact the conduct of the project.
- If your project involves radiation, you are legally obliged to conduct your research in accordance with the Australian Radiation Protection and Nuclear Safety Agency Code of Practice 'Exposure of Humans to Ionizing Radiation for

Research Purposes' Radiation Protection series Publication No.8 (May 2005)(ARPANSA Code).

Please note: Template forms for reporting Amendments, safety reporting, Annual/Final reports, etc. can be accessed from: <u>https://www.thermh.org.au/research/office-for-research/post-approval-project-management</u>

NSW sites

If your trial includes participants in NSW who may be incapable of providing valid consent to participate for themselves, the HREC suggest that you make yourself aware of the provisions of the *Medical Treatment Planning and Decisions Act 2016*. Prior to commencing your trial in NSW, you may need to make an application to the NSW Civil and Administrative Tribunal (NCAT) for approval for your trial to proceed as well as to provide direction on the appropriate consent mechanism. Please note that the Act contains serious penalties for conducting clinical trial research on non-competent participants without proper authorisation.

The HREC may conduct an audit of the project at any time.

Yours sincerely,

lseymour

Dr Catherine Seymour Deputy Chair – Royal Melbourne Hospital Human Research Ethics Committee (HREC)